Search clinical trials for: satoreotide trizoxetan

Total 5 results

Ipsen

Terminated

Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer

Breast Cancer

Austria
Ipsen

Completed

68Ga-OPS202 Study for Diagnostic Imaging of GEP NET

Gastroenteropancreatic Neuroendocrine Tumors

Switzerland
Ipsen

Completed

To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Gastro-Enteropancreatic Neuroendocrine Tumor

United States, Austria, Denmark
Ipsen

Terminated

Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2) (SSTR2+)

Small Cell Lung Cancer and Breast Cancer

United States, Austria, France, Switzerland, Germany, United Kingdom, Belgium
Ipsen

Terminated

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

Neuroendocrine Tumors

United States, Australia, Austria, Canada, Denmark, France, Switzerland, United Kingdom

3

Subscribe